sln360
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2020 (NCT04606602)
Timeline
Indications
Mechanism of action
- Apolipoprotein A-IINHIBITOR
APOA1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05537571 | Phase 2 | Dec 31, 2022 | Silence Therapeutics GmbH |
| NCT04606602 | Phase 1 | Nov 18, 2020 | Medpace, Inc., Silence Therapeutics GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Silence Therapeutics GmbH | For profit | 2 | 2 | 2 | 2020 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1